Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002752 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002752 is a Phase 1 study that has completed, run by Duke University.
The verdict
NCT00002752, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have primary or metastatic brain cancer.
Interventions
- RADIATION iodine I 131 monoclonal antibody 81C6
Trial Details
| Field | Value |
|---|---|
| Start Date | 1993-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002752
The ClinicalTrials.gov registry entry for NCT00002752 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iodine I 131 monoclonal antibody 81C6 is the first listed.
NCT00002752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002752 about?
NCT00002752 is a clinical study titled "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have primary ...
What is the current status of trial NCT00002752?
This trial is currently completed. It is a Phase 1 study. The study started on 1993-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00002752?
The interventions under investigation include: iodine I 131 monoclonal antibody 81C6 (RADIATION).
Who is sponsoring clinical trial NCT00002752?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.